Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Equity Income (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Equity Income for 7 consecutive years, with $678000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Income changed 0.0% to $678000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.0 million, a 144.62% decrease, with the full-year FY2024 number at -$1.1 million, down 380.86% from a year prior.
  • Equity Income was $678000.0 for Q3 2025 at Ultragenyx Pharmaceutical, up from -$9000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $25.7 million in Q3 2021 to a low of -$31.0 million in Q2 2021.
  • A 5-year average of -$3.2 million and a median of -$334000.0 in 2023 define the central range for Equity Income.
  • Biggest YoY gain for Equity Income was 1221.56% in 2024; the steepest drop was 1629.12% in 2024.
  • Ultragenyx Pharmaceutical's Equity Income stood at -$16.1 million in 2021, then surged by 111.43% to $1.8 million in 2022, then rose by 2.66% to $1.9 million in 2023, then plummeted by 181.95% to -$1.5 million in 2024, then skyrocketed by 143.8% to $678000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Equity Income are $678000.0 (Q3 2025), -$9000.0 (Q2 2025), and -$157000.0 (Q1 2025).